SCHEMBL16134355

SCHEMBL16134355

Cc1ccc(Cl)c(Nc2ccc(Cl)c3nonc23)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.43
MEN1 O00255 7/20 0.43
IDO1 P14902 1/20 0.42
TNF P01375 1/20 0.40
MAPK1 P28482 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
RAPGEF4 Q8WZA2 2/20 0.37
MYC P01106 1/20 0.36
MAX P61244 1/20 0.36
MAPT P10636 3/20 0.35
NPC1 O15118 2/20 0.35
POLB P06746 2/20 0.35
OPRD1 P41143 2/20 0.35
OPRK1 P41145 2/20 0.35
TLR9 Q9NR96 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16137801 0.81 MEN1 (0.51) KMT2AMEN1IDO1L3MBTL1TDP1
SCHEMBL14933670 0.73 IDO1 (0.69) KMT2AMEN1IDO1L3MBTL1MYC
SCHEMBL5303826 0.71 ATM (0.57) KMT2AMEN1MAPK1L3MBTL1MAPT
SCHEMBL19269465 0.71 MAPT (0.42) KMT2AMEN1TNFMAPK1L3MBTL1
SCHEMBL14933689 0.68 TNF (0.83) KMT2AMEN1TNFMAPK1L3MBTL1
SCHEMBL10240415 0.68 TNF (0.39) KMT2AMEN1TNFMAPK1L3MBTL1
SCHEMBL3500163 0.68 GLO1 (0.41) KMT2AMEN1MAPK1MAPTNPC1
SCHEMBL20440865 0.68 MAPT (0.44) KMT2AMEN1MAPK1L3MBTL1MAPT
SCHEMBL10412855 0.66 HPGD (0.52) KMT2AMEN1MAPK1TDP1RAPGEF4
SCHEMBL11190236 0.66 ADRA2A (0.52) KMT2AMEN1MAPK1MAPTOPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096554-B2 Drugs for inhibiting p38 and uses thereof Universidad Autónoma de Madrid (ES) 2015-08-04 US disclosed
US-20140296308-A1 DRUGS FOR INHIBITING P38 AND USES THEREOF Universidad Autónoma de Madrid (ES) 2014-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296308-A1 DRUGS FOR INHIBITING P38 AND USES THEREOF MAPK1, MAPK4, MAPK8 KMT2A 3069/4885MEN1 3940/4885IDO1 1545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.